Latest Conference Articles

June 2nd 2019, 3:30pm

ASCO Annual Meeting

Pre-Medicare-aged women with ovarian cancer were more likely to be diagnosed at an early stage and receive treatment within 30 days of diagnosis after passage of the Affordable Care Act than before.

June 2nd 2019, 4:24am

ASCO Annual Meeting

Kim N. Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses the results of the phase III TITAN trial, which evaluated apalutamide versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

June 2nd 2019, 3:23am

ASCO Annual Meeting

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the MONALEESA-7 trial in hormone receptor-positive breast cancer.

June 2nd 2019, 1:54am

ASCO Annual Meeting

A consortium of cancer care institutions released details on a prototype system designed to link electronic health record systems to provide a source of real-world patient information to guide research and improve cancer treatment.

June 1st 2019, 11:04pm

ASCO Annual Meeting

The development of tyrosine kinase inhibitors has revolutionized the treatment of EGFR-mutant non–small cell lung cancer in recent years, but new strategies are needed to overcome resistance mechanisms that promote disease recurrence.

June 1st 2019, 8:33pm

ASCO Annual Meeting

Adding apalutamide to androgen deprivation therapy (ADT) reduced the risk of the death by 33% in patients with metastatic castration-sensitive prostate cancer compared with ADT alone.

June 1st 2019, 3:32pm

ASCO Annual Meeting

Frontline pembrolizumab demonstrated non-inferior overall survival compared with standard chemotherapy among patients with PD-L1–positive, HER2-negative, advanced gastric or gastroesophageal junction cancer.

June 1st 2019, 3:32pm

ASCO Annual Meeting

Ribociclib plus endocrine therapy demonstrated an estimated overall survival rate of 70.2% at 42 months compared 46.0% for placebo and endocrine therapy in premenopausal women with HR-positive, HER2-negative advanced breast cancer.

June 1st 2019, 3:31pm

ASCO Annual Meeting

After 5 years, newly diagnosed patients with advanced non–small cell lung cancer demonstrated an overall survival (OS) rate of 23.2% from treatment with pembrolizumab monotherapy and previously treated patients had an OS rate of 15.5%.

June 1st 2019, 5:28am

ASCO Annual Meeting

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses updates in CAR T-cell therapy that are being presented at the 2019 ASCO Annual Meeting.

June 1st 2019, 4:43am

ASCO Annual Meeting

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, discusses part 1 findings from the phase III TALAPRO-2 trial in metastatic castration-resistant prostate cancer.

May 29th 2019, 1:59am

ASCO Annual Meeting

Within the week, thousands of abstracts spanning a multitude of tumor types will be presented at the 2019 ASCO Annual Meeting, many of which will lead to practice-changing implications for oncologists.

May 16th 2019, 1:34am

ASCO Annual Meeting

Entrectinib induced objective responses in 100% of pediatric patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions or mutations.

May 16th 2019, 1:01am

ASCO Annual Meeting

About a quarter of pediatric patients with cancer were able to be screened for targetable alterations in their tumor and directed to a treatment targeting that alteration of pathway in the screening protocol of the National Cancer Institute-Children’s Oncology Group Pediatric MATCH trial.

May 16th 2019, 1:00am

ASCO Annual Meeting

A lower dose of oxaliplatin and capecitabine had comparable efficacy and minimized adverse events in elderly and frail patients with advanced gastroesophageal cancer.

May 16th 2019, 1:00am

ASCO Annual Meeting

In patients with smoldering multiple myeloma, lenalidomide induced a 72% reduction in the risk for progression to symptomatic disease at 3 years.

May 16th 2019, 12:59am

ASCO Annual Meeting

Women who eat a balanced, low-fat diet and daily portions of vegetables, fruit, and grains have a 21% lower risk of dying from breast cancer.

April 14th 2019, 3:05am

European Lung Cancer Congress

Atezolizumab plus bevacizumab, carboplatin, and paclitaxel has emerged as a potential new standard of care for patients with EGFR-positive metastatic nonsquamous non–small cell lung cancer who have failed prior TKIs.

April 13th 2019, 10:19pm

European Lung Cancer Congress

Niels Reinmuth, MD, PhD, discusses the results of the MYSTIC study, which evaluated first-line durvalumab plus tremelimumab versus platinum-based chemotherapy in patients with metastatic non–small cell lung cancer.

April 13th 2019, 9:53pm

European Lung Cancer Congress

James Chih-Hsin Yang, MD, discusses the final safety and efficacy results from 2 phase I expansion cohorts from the phase I/II AURA trial.